Pfizer CEO Albert Bourla moved with his senior management team to Donald Trump’s Mar-a-Lago resort for an off-site meeting, in the latest attempt by US companies to get closer to the US president-elect.

Bourla and several members of his executive command arrived in Palm Beach, Florida, on Monday evening, according to flight records and two people familiar with the matter.

PfizerMar-a-Lago’s executive team uses a planning meeting over several days, the people said. Although there is no meeting scheduled between Bourla and Trump, the duo will likely interact and the choice of venue is another example of outreach from the pharmaceutical industry to Trump, a person familiar with the meeting said.

Drug company executives were preparing to appoint former independent presidential candidate Robert F. Kennedy, a vaccine skeptic, and his allies to run powerful U.S. health departments and agencies, such as the Food and Drug Administration and the Centers for Disease Control and Prevention. Kennedy and his advisers have sown seeds of doubt about the widespread rollout of vaccines and a new class of blockbuster weight-loss drugs.

After being contacted by the Financial Times, Pfizer confirmed that the meeting would be hosted at Mar-a-Lago. Trump’s transition team did not immediately respond to a request for comment.

Bourla, who worked closely with the Trump administration on developing a COVID-19 vaccine, has been leading the charge to court the president-elect.

Bourla met with Trump at Mar-a-Lago in the run-up to the November election, then was instrumental in organizing a dinner in December with Trump, Kennedy, Eli Lilly CEO David Ricks, and Steven Uppel, PhRMA’s president, Industry. The pressure group people said.

Bourla is among a growing list of corporate executives trying to foster a direct relationship with Trump ahead of his inauguration on January 20. Meta CEO Mark Zuckerberg, Amazon founder Jeff Bezos, and Apple CEO Tim Cook all dined with Trump at the Mar-a. -Lago in recent weeks.

Pfizer is also among several companies, including Meta and Amazon, that have pledged money to Trump’s inauguration committee, one of the people said.

Although the drug industry is wary of Kennedy’s nomination, some executives hope they can help shape a mutually beneficial policy agenda, according to lobbyists in Washington.

“Everyone knows where Donald Trump is going on immigration and energy, but there are a lot of nuances that could have multi-billion-dollar impacts on Big Tech and pharmaceutical companies,” said Matt Moyers, a former Trump official who runs the lobbying firm Valcor. “Those nuances are areas where these companies need to start working with the next administration.”

“If I were a pharmaceutical CEO, I would go to Mar-a-Lago, too,” said John LaMattina, a former head of research and development at Pfizer. “Trump likes people to come and pay their respects, and he listens when they come. So what’s better than going straight to the president-elect and pleading your case?”

Among the issues industry executives believe they can collaborate on with the new administration are reforms to pharmacy benefit managers, companies that negotiate drug prices on behalf of employers, insurers and state-subsidized health insurance programs, LaMattina said. These companies have been severely criticized for making huge profits. The executives also hope to work with Kennedy in his efforts to shake up the food industry as part of his “Make America Healthy Again” agenda.

Pfizer, one of the world’s largest vaccine manufacturers, was among many pharmaceutical stocks whose trading declined after Kennedy announced Trump’s nomination to run the US Department of Health. In December, Kennedy met with more than 20 Republican senators to discuss his plans for the role ahead of his confirmation hearing.